US regulatory status: approved.
pharma · Carcinoma, Renal Cell · Human Immunodeficiency Virus (HIV) Infection
Merck KGaA, Darmstadt
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt drug portfolio — 50 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Frankfurter Str. 250, Darmstadt, 64293, DE HQ
7,364 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Frankfurter Str. 250, Darmstadt, 64293, DE
- Employees
- 7,364
- Programs
- 63
- Drugs
- 50
- Patents
- 0
Merck KGaA, Darmstadt pipeline
Portfolio lens on 50 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Merck KGaA, Darmstadt drug portfolio — 50 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor antagonist
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Merck KGaA, Darmstadt's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
belzutifan
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Endothelial PAS domain-containing protein 1.
- Target
- Endothelial PAS domain-containing protein 1
- Mechanism
- Endothelial PAS domain-containing protein 1 inhibitor
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cetrorelix
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Merck KGaA, Darmstadt's portfolio. Mechanism: Gonadotropin-releasing hormone receptor antagonist.
- Mechanism
- Gonadotropin-releasing hormone receptor antagonist
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
choriogonadotropin alfa
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Lutropin-choriogonadotropic hormone receptor.
- Target
- Lutropin-choriogonadotropic hormone receptor
- Mechanism
- Luteinizing hormone/Choriogonadotropin receptor agonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cladribine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
clesrovimab
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Merck KGaA, Darmstadt's portfolio. Molecular target: Fusion glycoprotein F0.
- Target
- Fusion glycoprotein F0
- Mechanism
- Fusion glycoprotein F0 inhibitor
-
daptomycin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
doravirine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
follitropin alfa
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Merck KGaA, Darmstadt's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Hyaluronic acid.
- Target
- Hyaluronic acid
- Mechanism
- Hyaluronic acid hydrolytic enzyme
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate-gated chloride channel.
- Target
- Glutamate-gated chloride channel
- Mechanism
- Glutamate-gated chloride channel modulator
-
lenvatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Merck KGaA, Darmstadt's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
lutropin alfa
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Merck KGaA, Darmstadt's portfolio. Molecular target: Lutropin-choriogonadotropic hormone receptor.
- Target
- Lutropin-choriogonadotropic hormone receptor
- Mechanism
- Luteinizing hormone/Choriogonadotropin receptor agonist
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
molnupiravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Merck KGaA, Darmstadt's portfolio. Molecular target: RNA.
- Target
- RNA
- Mechanism
- RNA disrupting agent
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
raltegravir
Antiinfectives for systemic use (J05)Antiinfectives for systemic use (J05) compound in Merck KGaA, Darmstadt's portfolio.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records.
-
tepotinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Merck KGaA, Darmstadt's portfolio. Molecular target: Hepatocyte growth factor receptor.
- Target
- Hepatocyte growth factor receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
teriflunomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydroorotate dehydrogenase (quinone), mitochondrial.
- Target
- Dihydroorotate dehydrogenase (quinone), mitochondrial
- Mechanism
- Dihydroorotate dehydrogenase inhibitor
-
vericiguat
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Soluble guanylate cyclase.
- Target
- Soluble guanylate cyclase
- Mechanism
- Soluble guanylate cyclase activator
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Histone deacetylase 1.
- Target
- Histone deacetylase 1
- Mechanism
- Histone deacetylase 3 inhibitor
-
Development asset linked to Merck KGaA, Darmstadt in public FDA and regional records. Molecular target: Inactive tyrosine-protein kinase transmembrane receptor ROR1.
- Target
- Inactive tyrosine-protein kinase transmembrane receptor ROR1
- Mechanism
- Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor